ClinicalTrials.gg
CompletedNCT00445172Updated Jun 18, 2023

A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)

A Phase 2/3 interventional study of E0302 (mecobalamin) in Amyotrophic Lateral Sclerosis (ALS), sponsored by Eisai Co., Ltd.. Completed at 42 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Eisai Co., Ltd. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
135
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan — 2 open to participants now, 4 under way, 2 of them phase 3. Amyotrophic Lateral Sclerosis · Japan.

Enrollment
11th of 20
135 · median 136
Started
2008
the only one that year
Phase 2/3
2 of 21
none open now
Registered
2nd of 21
by date
Lead sponsor
3 of 21
Eisai Co., Ltd.

Among the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, this one is the 11th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2008, is one of 2 in phase 2/3, and was the 2nd registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

2 of the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the safety and efficacy of long-term E0302 administration in patients with Amyotrophic Lateral Sclerosis (ALS).

03

Conditions studied

  • Amyotrophic Lateral Sclerosis (ALS)

Keywords

  • Amyotrophic Lateral Sclerosis
  • Motor Neurons
  • Muscular Atrophy
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who have completed Phase II/III study of E0302 (E0302-J081-761, hereafter referred to as Study 761) except for those patients who discontinued the treatment of Study 761. Completed patients are defined as those who completed the treatment period of Study 761, those on 24-hour use of non-invasive positive pressure ventilation (NIPPV), or those who eventually resulted in the use of NIPPV.
  2. Patients who are able to submit written . If patients are duly capable of study consent but are unable to sign (or affix a seal) by themselves due to aggravation of disease condition, written informed consent can be obtained from a legally authorized representative who can sign on behalf of the patients after confirming the patients' agreement to study participation.

Exclusion criteria

Exclusion Criteria:

  1. Patients with cognitive impairment.
  2. Pregnant women or women who may have a possibility of becoming pregnant.
  3. Patients or their partners who are not willing to use reliable .
  4. Patients with severe disease in the renal, cardiovascular, hematological, or hepatic system (severe disease will be judged referring to "Ministry of Health, Labor and Welfare (MHLW) Drug Safety Dept. Notification No. 80, Drug Safety Classification Criteria for Severity of Adverse Drug Reaction by Medicinal Products, Grade 3." However, an event due to the primary disease will be precluded).
  5. Patients with malignant tumor.
  6. Patients who participated in another clinical study after the completion of Study 761.
  7. Patients with present illness or history of drug allergy or severe allergic disease (anaphylactic shock).
  8. Patients who are judged to be ineligible for study entry by the investigator or subinvestigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    1

    Drug: E0302 (mecobalamin)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events as a Measure of safety

    Time frame: Every 3 months

Secondary outcomes

  1. Survival rate

    Time frame: Every 3 months

  2. Functional rating scale

    Time frame: Every 3 months

  3. Percent-predicted forced vital capacity (%FVC.)

    Time frame: Every 3 months

07

Study locations

42 sites
  • Nagoya-shi, Aichi, Japan
  • Aomori-shi, Aomori, Japan
  • Chiba-shi, Chiba, Japan
  • Touon-shi, Ehime, Japan
  • Fukuoka-shi, Fukuoka, Japan
  • Kitakyushi-shi, Fukuoka, Japan
  • Fukushima-shi, Fukushima, Japan
  • Maebashi-shi, Gunma, Japan
  • Higashihiroshima-shi, Hiroshima, Japan
  • Miyoshi-shi, Hiroshima, Japan
  • Otake-shi, Hiroshima, Japan
  • Sapporo-shi, Hokkaido, Japan
  • Kanazawa-shi, Ishikawa, Japan
  • Ichinoseki-shi, Iwate, Japan
  • Sagamihara-shi, Kanagawa, Japan
  • Yokohama-shi, Kanagawa, Japan
  • Nangoku-shi, Kochi, Japan
  • Kyoto-shi, Kyoto, Japan
  • Tsu-shi, Mie, Japan
  • Sendai-shi, Miyagi, Japan
  • Watari-gun, Miyagi, Japan
  • Nagano-shi, Nagano, Japan
  • Higashisonogi-gun, Nagasaki, Japan
  • Kashiwazaki-shi, Niigata, Japan
  • Niigata-shi, Niigata, Japan
  • Tsukubo-gun, Okayama, Japan
  • Ginowan-shi, Okinawa, Japan
  • Toyonaka-shi, Osaka, Japan
  • Hasuda-shi, Saitama, Japan
  • Saitama-shi, Saitama, Japan
  • Hamamatsu-shi, Shizuoka, Japan
  • Shizuoka-shi, Shizuoka, Japan
  • Shimotsuke-shi, Tochigi, Japan
  • Tokushima-shi, Tokushima, Japan
  • Yoshinogawa-shi, Tokushima, Japan
  • Bunkyo-ku, Tokyo, Japan
  • Kodaira-shi, Tokyo, Japan
  • Ota-ku, Tokyo, Japan
  • Wakayama-shi, Wakayama, Japan
  • Yonezawa-shi, Yamagata, Japan
  • Shimonoseki-shi, Yamaguchi, Japan
  • Yanai-shi, Yamaguchi, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2008 to primary completion in Mar 2017, 109 months.

Of 22 phase 2/3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 109. This study's 109 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2007
First posted
Mar 8, 2007
StartActual
Feb 2008
Primary completionActual
Mar 31, 2017
CompletionActual
Mar 31, 2017
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00445172
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Mar 8, 2007
Start date
Feb 2008
Primary completion
Mar 31, 2017
Completion
Mar 31, 2017
Last update
Jun 18, 2023

Study contacts

Kazunori Saeki
study director · Neuroscience Clinical Development Section. JAC PCU. Eisai Co., Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mecobalamin

Start the discussion